n.a. (SHP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

Shire Announces U.S. FDA Approval Of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment For Primary Immunodeficiency

Shire Announces U.S. FDA Approval Of CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment For Primary Immunodeficiency

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites

Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

Shire's First Prescription Eye Drop, Xiidra™ (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

- Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI [von Willebrand factor (Recombinant)] is a significant advancement for the treatment of adults with von Willebrand disease (VWD)

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

New system reduces number of steps in the treatment process for hemophilia A patients on ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

Shire committed to advancing treatment and raising standards of care for hemophilia patients around the world

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

More than 40 presentations and sessions feature broad pipeline and proven factor replacement portfolio, with new innovation on outcomes, safety and efficacy measures

Shire And Kamada Announce FDA Approval Of Expanded Label For Self-infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency

Shire And Kamada Announce FDA Approval Of Expanded Label For Self-infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency

GLASSIA [Alpha-1 Proteinase Inhibitor (Human)] is the only FDA approved alpha-1 antitrypsin (AAT) augmentation treatment that patients can self-infuse at home

Baxalta Shareholders Vote To Approve Combination

Baxalta Shareholders Vote To Approve Combination

Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this...